Cardiogeni PLC (CGNI)
Company background
Cardiogeni is a biotechnology company developing cell-based medicines for heart failure. Its research platform engineers living cells for therapeutic use, with lead candidate CLXR-001 being developed for administration during coronary artery bypass surgery. Its business centres on research, clinical development and potential licensing or commercialisation of these treatments. Development-stage medicines should not be confused with established, approved products.
Primary operations
- Cell therapy research
- Heart failure drug development
- Clinical development
Background sources and review date
Company background reviewed on . This review date does not indicate the date of the latest company announcement.
Follow Cardiogeni PLC free
Keep up with available company announcements in one watchlist. A free account lets you follow up to three companies. Email updates are optional.
No payment details required. Compare Free and Pro.
Read announcements with more context
Use these free guides alongside the figures and wording in the company's own announcements.
The interactive company page loads here when JavaScript is enabled. Announcement history and upcoming dates depend on available coverage. Edravo provides information, not personalised investment advice.